Treating Post-Lyme Disease Syndrome With Acetogenins

Post-Lyme Disease Syndrome (PLDS) Clinical Trial

Official title:

Using ReaLife+ to Treat Post-Lyme Disease Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04078841
• Other study ID #: RLP042019
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: July 1, 2019
• Est. completion date: January 30, 2020

Study information

• Verified date: February 2020
• Source: Optimal Health Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To access the effectiveness of Acetogenins in treating Post-Lyme Disease Syndrome (PLDS).

Description:

To access the effectiveness of Acetogenins in treating Post-Lyme Disease Syndrome (PLDS). After failure of antibiotic therapy to relive persistent symptoms of Lyme Disease, the use of Acetogenins to elevate Post-Lyme Disease Syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: January 30, 2020
• Est. primary completion date: November 14, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. A positive Western Blot for Lyme Disease that has been treated with antibiotics but the symptoms persist post treatment.

2. Must be able to swallow and mixed powder drink.

-

Exclusion Criteria:

1. Non Positive Western Blot test.

2. Positive Western Blot test where the indivual has not been treated with antibiotics.

-

Related Conditions & MeSH terms

• Lyme Disease
• Post-Lyme Disease Syndrome (PLDS)
• Syndrome

Intervention

Dietary Supplement:
• ReaLife+ (RLP)
RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.

Other:
• Inert Brown powder
Brown powder Inert brown powder to look similar to RLP

Locations

Country	Name	City	State
United States	Optimal Health Research	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Optimal Health Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood test	Western Blot showing "negative"	3 months
Primary	PROMIS Fatigue Scale	Self reported fatigue level changes as measured by the Patient-Reported Outcomes Measurement Information System, Fatigue Scale.	3 months